Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study.

ABSTRACT:

SUBMITTER: Mina R 

PROVIDER: S-EPMC7234990 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature